Intervention

Loperamide

ClinicalTrials.gov intervention label

Explore related research

Search across original and mapped records

Search results distinguish clinical terminology from original registry names. Shared trial participation does not imply treatment or approval.

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov intervention label, found in 14 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials14
Recruiting3
Common conditions25
Lead sponsors shown12
Advertisement

Clinical trials

14 shown
Rash & Diarrhea Prophylaxis With CapivasertibNCT07426822 · 2026-08-15
RECRUITING
Probiotics for Prevention of Neratinib-Induced Diarrhea in Breast Cancer PatientsNCT06892093 · 2025-08-07
RECRUITING
Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer PatientsNCT04038619 · 2021-02-01
RECRUITING
Preventive stRategy for IMMU132-relatED AEs in TNBC or Luminal Breast Cancer- PRIMEDNCT05520723 · 2023-02-06
COMPLETED
Three Antidiarrheal Strategies in HER2+/HR+ Early Breast Cancer Patients Treated With Extended Adjuvant NeratinibNCT05252988 · 2022-08-31
ACTIVE_NOT_RECRUITING
Effect of Montmorillonite Power or Loperamide on the Pharmacokinetics of Pyrotinib in Healthy SubjectsNCT05252546 · 2022-03-08
COMPLETED
A Study to Characterize Colon Pathology in Patients With HER2 Amplified Breast Cancer Treated With NeratinibNCT04366713 · 2020-06-30
COMPLETED
Prevention and Treatment of Pyrrolitinib-associated DiarrheaNCT04736186 · 2020-05-16
UNKNOWN
A Study of Poziotinib in Patients With Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Activating Mutations in Advanced MalignanciesNCT04172597 · 2019-12-23
TERMINATED
Incidence and Severity of Diarrhea in Patients With HER2 Positive Breast Cancer Treated With Trastuzumab and NeratinibNCT03094052 · 2018-10-09
COMPLETED
A Neoadjuvant Study of Abemaciclib (LY2835219) in Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Breast CancerNCT02441946 · 2015-08-01
COMPLETED
An Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients With Early-Stage HER2+ Breast Cancer Treated With Neratinib and LoperamideNCT02400476 · 2015-02-01
COMPLETED
Pilot Study to Assess Dimethyl Fumarate Related GI Symptom MitigationNCT02217982 · 2014-07-01
TERMINATED
A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has SpreadNCT02057133 · 2014-03-10
ACTIVE_NOT_RECRUITING

Common conditions

Trial status mix

COMPLETED6
RECRUITING3
ACTIVE_NOT_RECRUITING2
TERMINATED2
UNKNOWN1

Phase mix

PHASE29
PHASE13
NA1
PHASE31
PHASE41
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.